These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 21895036)

  • 1. Impact of pharmacometric analyses on new drug approval and labelling decisions: a review of 198 submissions between 2000 and 2008.
    Lee JY; Garnett CE; Gobburu JV; Bhattaram VA; Brar S; Earp JC; Jadhav PR; Krudys K; Lesko LJ; Li F; Liu J; Madabushi R; Marathe A; Mehrotra N; Tornoe C; Wang Y; Zhu H
    Clin Pharmacokinet; 2011 Oct; 50(10):627-35. PubMed ID: 21895036
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of pharmacometrics on drug approval and labeling decisions: a survey of 42 new drug applications.
    Bhattaram VA; Booth BP; Ramchandani RP; Beasley BN; Wang Y; Tandon V; Duan JZ; Baweja RK; Marroum PJ; Uppoor RS; Rahman NA; Sahajwalla CG; Powell JR; Mehta MU; Gobburu JV
    AAPS J; 2005 Oct; 7(3):E503-12. PubMed ID: 16353928
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of pharmacometric reviews on new drug approval and labeling decisions--a survey of 31 new drug applications submitted between 2005 and 2006.
    Bhattaram VA; Bonapace C; Chilukuri DM; Duan JZ; Garnett C; Gobburu JV; Jang SH; Kenna L; Lesko LJ; Madabushi R; Men Y; Powell JR; Qiu W; Ramchandani RP; Tornoe CW; Wang Y; Zheng JJ
    Clin Pharmacol Ther; 2007 Feb; 81(2):213-21. PubMed ID: 17259946
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacometrics for regulatory decision making: status and perspective.
    Manolis E; Herold R
    Clin Pharmacokinet; 2011 Oct; 50(10):625-6. PubMed ID: 21895035
    [No Abstract]   [Full Text] [Related]  

  • 5. Requirements for submission of labeling for human prescription drugs and biologics in electronic format. Final rule.
    Food and Drug Administration, HHS
    Fed Regist; 2003 Dec; 68(238):69009-20. PubMed ID: 14672084
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Assessment of the quality and quantity of drug-drug interaction studies in recent NDA submissions: study design and data analysis issues.
    Huang SM; Lesko LJ; Williams RL
    J Clin Pharmacol; 1999 Oct; 39(10):1006-14. PubMed ID: 10516934
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Leveraging prior quantitative knowledge to guide drug development decisions and regulatory science recommendations: impact of FDA pharmacometrics during 2004-2006.
    Wang Y; Bhattaram AV; Jadhav PR; Lesko LJ; Madabushi R; Powell JR; Qiu W; Sun H; Yim DS; Zheng JJ; Gobburu JV
    J Clin Pharmacol; 2008 Feb; 48(2):146-56. PubMed ID: 18199891
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Supplemental applications proposing labeling changes for approved drugs, biologics, and medical devices. Final rule.
    Food and Drug Administration, HHS
    Fed Regist; 2008 Aug; 73(164):49603-10. PubMed ID: 18958946
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Innovative early development regulatory approaches: expIND, expCTA, microdosing.
    Robinson WT
    Clin Pharmacol Ther; 2008 Feb; 83(2):358-60. PubMed ID: 18091759
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Communicating with the FDA: the "third rail" of a new model for drug development.
    Stanski DR; Orloff JJ
    J Clin Pharmacol; 2008 Feb; 48(2):144-5. PubMed ID: 18199890
    [No Abstract]   [Full Text] [Related]  

  • 11. New FDA breakthrough-drug category--implications for patients.
    Darrow JJ; Avorn J; Kesselheim AS
    N Engl J Med; 2014 Mar; 370(13):1252-8. PubMed ID: 24670173
    [No Abstract]   [Full Text] [Related]  

  • 12. FDA review divisions: performance levels and the impact on drug sponsors.
    Milne CP; Kaitin KI
    Clin Pharmacol Ther; 2012 Mar; 91(3):393-404. PubMed ID: 22336592
    [TBL] [Abstract][Full Text] [Related]  

  • 13. They are from the government and they really are here to help you.
    Woosley RL
    J Clin Pharmacol; 2008 Feb; 48(2):142-3. PubMed ID: 18199889
    [No Abstract]   [Full Text] [Related]  

  • 14. Lessons learned from independent central review.
    Ford R; Schwartz L; Dancey J; Dodd LE; Eisenhauer EA; Gwyther S; Rubinstein L; Sargent D; Shankar L; Therasse P; Verweij J
    Eur J Cancer; 2009 Jan; 45(2):268-74. PubMed ID: 19101138
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Trial endpoints for drug approval in oncology: Chemoprevention.
    Beitz J
    Urology; 2001 Apr; 57(4 Suppl 1):213-5. PubMed ID: 11295630
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacometrics at FDA: evolution and impact on decisions.
    Powell JR; Gobburu JV
    Clin Pharmacol Ther; 2007 Jul; 82(1):97-102. PubMed ID: 17538553
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The new drug approvals of 1990, 1991, and 1992: trends in drug development.
    Kaitin KI; Manocchia M; Seibring M; Lasagna L
    J Clin Pharmacol; 1994 Feb; 34(2):120-7. PubMed ID: 8163711
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Review of Patient-Reported Outcome Labeling in the United States (2011-2015).
    Gnanasakthy A; Mordin M; Evans E; Doward L; DeMuro C
    Value Health; 2017 Mar; 20(3):420-429. PubMed ID: 28292487
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Analysis of US Food and Drug Administration review intervals for drugs approved during the period 1997-2002.
    Kros JF; Qian J
    Am J Ther; 2004; 11(5):337-43. PubMed ID: 15356429
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Drug interaction studies on new drug applications: current situations and regulatory views in Japan.
    Nagai N
    Drug Metab Pharmacokinet; 2010; 25(1):3-15. PubMed ID: 20208385
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.